Parsortix technology is a unique method for capturing and harvesting intact circulating tumour cells (CTCs) and CTC clusters from whole blood for downstream analysis
CTCs are cancer cells that have detached from the primary tumour and entered the circulation. They are extremely rare in the blood and are often referred to as “a needle in a haystack”.
- As well as being functional cancer cells, CTCs play a critical role in initiating metastasis and are therefore a focus of cancer research and personalised medicine
- By harvesting viable CTCs, Parsortix technology enables comprehensive profiling of cancer cells in a non-invasive, repeatable manner
The Parsortix platform uses a patented microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood cells
Learn more about Parsortix® technology in the latest publications
Discover moreParsortix technology
Take a closer look at CTC harvesting in action
Discover how you can bring the power of Parsortix platform into your laboratory
Parsortix platform
Discover moreParsortix platform
The patented Parsortix platform allows the enrichment circulating tumour cells (CTCs) from peripheral blood from patients diagnosed with cancer. The system employs a microfluidic chamber (a Parsortix® cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix platform for use in subsequent downstream assays.
References
- Dive C, Brady G. SnapShot: circulating tumor cells. Cell. 2017 Feb 9;168(4):742-.
- Castro-Giner F, Aceto N. Tracking cancer progression: From circulating tumor cells to metastasis. Genome Medicine. 2020 Dec;12(1):1-2.